
Immunome (IMNM) Stock Forecast & Price Target
Immunome (IMNM) Analyst Ratings
Bulls say
Immunome Inc. is advancing its clinical pipeline, with a strong focus on oncology and infectious diseases, and is preparing for the RINGSIDE Phase 3 data involving Varegacestat, which is viewed as potentially differentiated in its class. The company's strategy aims to deliver demonstrably superior outcomes in objective response rates (ORR), tumor volume, and symptom reductions, which are crucial for commercial success. This strategic positioning, along with the promising development of multiple assets, contributes to a favorable risk/reward outlook for the company's stock.
Bears say
Immunome Inc has experienced a significant decline in its stock performance, with shares underperforming by 55% since the announcement of the varegacestat acquisition on February 6, 2024. The company's bear case scenario suggests a potential share value of approximately $5-$7 if varegacestat proves inferior compared to competing treatments and fails to gain approval or achieves minimal sales. Additionally, Immunome faces various risks including research and development challenges, regulatory hurdles, competition, and the likelihood of lower than expected product sales, all of which contribute to a negative outlook on its financial prospects.
This aggregate rating is based on analysts' research of Immunome and is not a guaranteed prediction by Public.com or investment advice.
Immunome (IMNM) Analyst Forecast & Price Prediction
Start investing in Immunome (IMNM)
Order type
Buy in
Order amount
Est. shares
0 shares